Genmab A/S has been making headlines recently for various reasons. The company smashed stock trading on Monday, with several analysts naming it as a potentially profitable growth stock. The company's share buy-back program has been progressed significantly, with a noticeable uptick in transactions. Despite some recent underperformance in biotech and healthcare sectors, the overall outlook for the firm remains positive. Unfortunately, the company also faced criticisms for its recent drop in performance, causing one analyst to term it among the worst-performing biotech stocks. However, encouraging antitumor data from its oncology portfolio, strong demand for
Darzalex, and promising results from the initial
Rina-S study positive outlook. Controversies surrounding
AbbVie's lawsuit and
J&J exiting the
HexaBody-CD38 collaboration have negatively impacted the stock's performance risking the price target cuts from major banks. Nevertheless, the institution still sees significant growth potential, including a forecast of a 19% revenue growth and a 62% surge in operating profit for Q1 2025.
Genmab has maintained its innovative edge, launching a $610 million share buy-back program and making strides towards transitioning from the royalty model to commercial-stage oncology.
Genmab Stocks News Analytics from Thu, 15 Feb 2024 08:00:00 GMT to Fri, 20 Jun 2025 07:00:00 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor -3
